QiongZhaoMDPhD

Cardiology • Falls Church, VA

Adult Congenital Heart Disease

Assistant Professor in Medicine-Cardiology, Northwestern University Medical School

Join to view full profile

Dr. Zhao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zhao's full profile

Already have an account?

Office
3300 Gallows Rd
Falls Church, VA 22042
Phone+1 703-776-4001

Fax+1 703-776-7113

Education & Training

University of Illinois College of Medicine at ChicagoFellowship, Cardiovascular Disease, 2003 - 2006
University of Kansas School of MedicineResidency, Pathology-Anatomic and Clinical, 1999 - 2004
UMass Chan Medical SchoolResidency, Internal Medicine, 2000 - 2003
Beijing Medical UniversityClass of 1993

Certifications & Licensure

VA State Medical License 2014 - 2026
IN State Medical License 2013 - 2015
IL State Medical License 2003 - 2014

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Fellow (FACC) American College of Cardiology

Clinical Trials

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC Start of enrollment: 2013 Dec 01
Unknown status
Phase 2
Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma Start of enrollment: 2014 Jan 01
Withdrawn
Phase 2
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer Start of enrollment: 2014 Jan 01
Unknown status
Phase 2
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus Start of enrollment: 2014 Jan 01
Withdrawn
Phase 2
Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma Start of enrollment: 2014 Feb 01
Withdrawn
Phase 2
Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus Start of enrollment: 2014 Feb 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

The active ingredient β-sitosterol in Ganoderma regulates CHRM2-mediated aerobic glycolysis to induce apoptosis of lung adenocarcinoma.
Qiong Zhao, Yuting Pan, Danjia Zhang, Xiaolian Zhou, Liangyun Sun
Genes & Genetic Systems. 2024-11-14
1 citations
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.
Jin-Ji Yang, Jianying Zhou, Si-Yang Maggie Liu, Mingjun Li, Zhiye Zhang
The Lancet. Respiratory Medicine. 2024-09-01
Artificial Intelligence Assessment of Biological Age From Transthoracic Echocardiography: Discrepancies with Chronologic Age Predict Significant Excess Mortality.
Kobi Faierstein, Michael Fiman, Ranel Loutati, Noa Rubin, Uri Manor
Journal of the American Society of Echocardiography. 2024-08-01

Press Mentions

CAR-T Tx Shifts into First Gear in Lung CancerOctober 7th, 2018

Professional Memberships

American College of Cardiology - ACC
Member

Other Languages

Chinese (Mandarin)